Biodesix, Inc (BDSX)

Etorro trading 970x250

About Biodesix, Inc

Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company offers blood-based tests across the lung cancer continuum of care, such as Nodify XL2 and Nodify CDT tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules; and GeneStrat tumor profiling and VeriStrat immune profiling tests that provide physicians with timely results to facilitate treatment decisions. It also provides Bio-Rad SARS-CoV-2 ddPCR test, which is designed to detect the presence of infection by the SARS-CoV-2 virus; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. In addition, the company offers include diagnostic research, clinical research, development, and testing services to biopharmaceutical companies, as well as discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado. Address: 2970 Wilderness Place, Boulder, CO, United States, 80301

Biodesix, Inc News and around…

Latest news about Biodesix, Inc (BDSX) common stock and company :

Local med tech startup Spesana partners with Colorado-based public company Biodesix Inc. to provide more molecular diagnostic tests
01 Dec, 2021 Yahoo! Finance

Spesana has partnered with Biodesix Inc., a Colorado-based diagnostics solutions business that provides molecular diagnostics tests, with a focus on lung cancer.

Biodesix Partners with Spesana to Streamline Digital Access to Molecular Diagnostics for Precision Medicine in Lung Cancer
01 Dec, 2021 FinancialContent

Spesana, the developer of a novel electronic operating system to unify EMRs, and Biodesix Inc. (NSDQ: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that they have partnered to further streamline and automate the use of molecular diagnostics in clinical workflows across the United States utilizing Spesana’s digital platform solutions for comprehensive lung cancer management. Spesana is a cloud based Digital Healthcare Platform unifying all EMRs, Lab Information Systems and Molecular Diagnostics to improve what is often considered a broken electronic healthcare system that all too frequently turns what should be simple tasks into complex problems for healthcare providers. The platform automates referral management, tumor boards, molecular test orders, results, and clinical trial management. Spesana breaks down therapeutic silos by providing a unified health record allowing healthcare providers to ensure patients receive precision treatments and/or opportunities to enroll in clinical trials.

Things Look Grim For Biodesix, Inc. (NASDAQ:BDSX) After Today's Downgrade
25 Nov, 2021 Yahoo! Finance

Market forces rained on the parade of Biodesix, Inc. ( NASDAQ:BDSX ) shareholders today, when the analysts downgraded...

Jack Schuler Is The Independent Director of Biodesix, Inc. (NASDAQ:BDSX) And Just Spent US$130k On Shares
24 Nov, 2021 Yahoo! Finance

Investors who take an interest in Biodesix, Inc. ( NASDAQ:BDSX ) should definitely note that the Independent Director...

Biodesix Announces Publication Highlighting Interim Data from the INSIGHT Study Assessing the Clinical Effectiveness of VeriStrat® Proteomic Test in the Journal of Immunotherapy of Cancer
18 Nov, 2021 FinancialContent

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced new interim data published from the large multi-center observational registry study INSIGHT (Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects) (NCT03289780) utilizing its novel predictive and prognostic blood-based host immune classifier (the VeriStrat test) to stratify Immune checkpoint inhibition (ICI) treatment response in patients with advanced non-small cell lung cancer(NSCLC). The study, titled “Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer,” was published in the Journal of Immunotherapy of Cancer (JITC) and can be viewed here.

Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2021
17 Nov, 2021 FinancialContent

Upgrades According to Williams Capital, the prior rating for On Holding AG (NYSE:ONON) was changed from Sell to Hold. ...

Biodesix, Inc. (BDSX) Q3 2021 Earnings Call Transcript
16 Nov, 2021 FinancialContent

BDSX earnings call for the period ending September 30, 2021.

Biodesix, Inc. (BDSX) Reports Q3 Loss, Tops Revenue Estimates
15 Nov, 2021 Yahoo! Finance

Biodesix, Inc. (BDSX) delivered earnings and revenue surprises of 0.00% and 8.85%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Biodesix Announces Third Quarter 2021 Results and Highlights
15 Nov, 2021 FinancialContent

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for the third quarter ended September 30, 2021 and provided a corporate update.

Biodesix to Present Data Supporting Proteomic-Based Immunotherapy Diagnostic Tests and AI Explainability in Diagnostic Tests at Society for Immunotherapy of Cancer Annual Meeting
12 Nov, 2021 FinancialContent

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the company will co-present with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), three posters at the 36th Annual Society for Immunotherapy of Cancer (SITC) Nov. 10 – 14, 2021 from research into diagnostic tests of treatment response of NSCLC patients to immune checkpoint inhibitor therapy.

Biodesix to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum
11 Nov, 2021 FinancialContent

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present in a fireside chat at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum being held virtually November 18, 2021.

Biodesix, Inc. (BDSX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
08 Nov, 2021 Yahoo! Finance

Biodesix, Inc. (BDSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biodesix to Report Third Quarter 2021 Financial Results on November 15, 2021
01 Nov, 2021 FinancialContent

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the third quarter ended September 30, 2021 before the open of trading on Monday, November 15. Biodesix’s management will host a conference call and webcast to discuss its financial results and provide a general business update at 9:00 a.m. Eastern Time on the same day. Dial-in and call details are as follows:

The past year for Biodesix (NASDAQ:BDSX) investors has not been profitable
28 Oct, 2021 Yahoo! Finance

Investors can approximate the average market return by buying an index fund. While individual stocks can be big...

Biodesix Announces New Data on Nodify Lung® Nodule Risk Assessment Testing at the CHEST 2021 Annual Meeting
13 Oct, 2021 FinancialContent

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company, today announced that multiple data presentations will occur at the 2021 annual CHEST virtual conference. Presentations will include newly emerging data from the post-market, prospective, real-world ORACLE study (An Observational Registry Study to Evaluate the Performance of the Nodify XL2® Test - ORACLE [NCT03766958]), demonstrating that incorporation of this blood-based test in the management of patients with newly detected lung nodules modified physician behavior. The prospectively collected data show the ability to reduce unnecessary invasive biopsies and surgeries, through incorporation of the Nodify XL2 test in clinical practice. The ORACLE Study Principal Investigator, Michael Pritchett, DO, MPH, Director, Chest Center of the Carolinas at FirstHealth and past President of the Society for Advanced Bronchoscopy, released new data based on the use of the Nodify XL2® test in a real-world clinical practice setting.

Implied VTWG Analyst Target Price: $269
27 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 Growth ETF (VTWG), we found that the implied analyst target price for the ETF based upon its underlying holdings is $268.76 per unit.

Biodesix's Return On Capital Employed Insights
22 Sep, 2021 FinancialContent

Biodesix (NASDAQ:BDSX) brought in sales totaling $11.88 million during Q2 according to data provided by Benzinga Pro. However, earnings ...

Biodesix Announces Abstracts Presented During the IASLC 2021 World Conference on Lung Cancer
16 Sep, 2021 FinancialContent

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that two abstracts highlighting proteomic and genomic data based on their diagnostic tests were presented at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (WCLC).

Biodesix to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference
02 Sep, 2021 FinancialContent

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present in a fireside chat the Morgan Stanley Virtual 19th Annual Global Healthcare Conference being held virtually September 9-10 and September 13-15, 2021.

Biodesix DeSoto Laboratory Receives both ISO 13485:2016 Certification and Accreditation from the College of American Pathologists
25 Aug, 2021 FinancialContent

Biodesix, Inc. (Nasdaq: BDSX). Today Biodesix announced that the Accreditation Committee of the College of American Pathologists (CAP) and British Standards Institute (BSI) on behalf of International Organization for Standardization (ISO) recently awarded both CAP accreditation and ISO 13485:2016 certification to the Biodesix Laboratory located in DeSoto, Kansas, based on results of two independent inspections conducted by CAP and BSI inspectors.

Biodesix DeSoto Laboratory Receives both ISO 13485:2016 Certification and Accreditation from the College of American Pathologists
25 Aug, 2021 Yahoo! Finance

BOULDER, Colo., August 25, 2021--Biodesix, Inc. (Nasdaq: BDSX). Today Biodesix announced that the Accreditation Committee of the College of American Pathologists (CAP) and British Standards Institute (BSI) on behalf of International Organization for Standardization (ISO) recently awarded both CAP accreditation and ISO 13485:2016 certification to the Biodesix Laboratory located in DeSoto, Kansas, based on results of two independent inspections conducted by CAP and BSI inspectors.

4 Stocks Insiders Are Buying
24 Aug, 2021 FinancialContent

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. ...

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
18 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

66 Biggest Movers From Yesterday
18 Aug, 2021 FinancialContent

Gainers Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) shares surged 265.5% to close at $15.35 on Tuesday after the company received ...

Top Buys by Directors: Schuler's $1.7M Bet on BDSX
17 Aug, 2021 FinancialContent

The directors of a company tend to have a unique inside view into the business, so when directors make major buys, investors are wise to take notice. Presumably the only reason a director of a company would choose to take their hard-earned cash and use it to buy stock in the open market, is that they expect to make money — maybe they find the stock very undervalued, or maybe they see exciting progress within the company, or maybe both..

The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
17 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

News Flash: 4 Analysts Think Biodesix, Inc. (NASDAQ:BDSX) Earnings Are Under Threat
16 Aug, 2021 Yahoo! Finance

Market forces rained on the parade of Biodesix, Inc. ( NASDAQ:BDSX ) shareholders today, when the analysts downgraded...

The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
13 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
12 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Why Did Biodesix Stock Fall 26% Today?
11 Aug, 2021 FinancialContent

Biodesix Inc's(NASDAQ: BDSX)second-quarter revenues grew 183% Y/Y to $11.9 million, but short of the$21.14 ...

Biodesix, Inc (BDSX) is a NASDAQ Common Stock listed in , ,

970x250